Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Cypress Bioscience Inc. (NasdaqSC:CYPB)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
4350 Executive Drive, Suite 325
San Diego, CA 92121
Phone: (858) 452-2323
Fax: (858) 452-1222
Employees (last reported count): 6
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 39%
·Institutional: 36% (59% of float)
(24 institutions)
·Net Inst. Buying: 125.0K shares (+5.16%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Cypress Bioscience Inc. is focused on the development of therapeutics for the treatment of rheumatologic disorders and has begun a program directed at the development of drug candidates for the treatment of fibromyalgia, a chronic pain condition. In addition, the Company has evaluated various possible strategic transactions, including the potential acquisitions of products, technologies and companies, and expects to continue to do so in the future. The Company is also continuing to develop Cyplex, a platelet alternative, as an alternative to traditional platelet transfusions.
More from Market Guide: Expanded Business Description

Financial Summary
Cypress Bioscience researches, develops, manufactures and markets medical devices and therapeutics for the treatment of immune disorders and develops therapeutic agents for the treatment of blood platelet disorders. For the six months ended 6/30/01, total revenues fell 43% to $800 thousand. Net loss fell 58% to $2.1 million. Revenues reflect the absence of reimbursement from Fresenius. Lower loss reflects the absence of a $3.6 million selling and marketing expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Jay Kranzler, M.D., Ph.D., 43
Chairman, CEO, Chief Financial Officer
$664K
John Bonfiglio, 46
Exec. VP, COO
--  
R. Michael Gendreau, M.D., Ph.D., 46
Exec. VP, R&D, CMO & Chief Scientific Officer
382K
Sabrina Johnson, 35
VP of Marketing
111K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqSC:CYPBAs of 31-Aug-2001
Price and Volume
52-Week Low
on 12-Apr-2001
$0.75 
Recent Price$4.10 
52-Week High
on 28-Sep-2000
$16.00 
Beta1.53 
Daily Volume (3-month avg)38.4K
Daily Volume (10-day avg)31.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-72.2%
52-Week Change
relative to S&P500
-62.7%
Share-Related Items
Market Capitalization$26.0M
Shares Outstanding6.34M
Float3.90M
Dividends & Splits
Annual Dividendnone 
Last Split: 1 for 8 on 12-Mar-2001
Per-Share Data
Book Value (mrq)$0.39 
Earnings (ttm)-$0.91 
Earnings (mrq)-$0.15 
Sales (ttm)$0.39 
Cash (mrq)$1.60 
Valuation Ratios
Price/Book (mrq)10.49 
Price/EarningsN/A 
Price/Sales (ttm)10.64 
Income Statements
Sales (ttm)$2.36M
EBITDA (ttm)-$5.46M
Income available to common (ttm)-$5.58M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-50.60%
Return on Equity (ttm)-123.14%
Financial Strength
Current Ratio (mrq)3.10 
Debt/Equity (mrq)0.54 
Total Cash (mrq)$10.2M
Short Interest
As of 8-Aug-2001
Shares Short38.0K
Percent of Float1.0%
Shares Short
(Prior Month)
10.0K
Short Ratio0.68 
Daily Volume56.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.